Donald L Deyo Appointed Chairman and Head of US Operations at LindaCare

LindaCare is pleased to announce the appointment of Donald L Deyo into the new roles of Executive Chairman of the LindaCare NV and President and CEO of the US subsidiary, LindaCare Inc.  Deyo served as Chairman of the Board for the Company since 2017.

LindaCare is a digital health company specializing in integrated remote cardiac monitoring solutions.  With operations in Europe and USA, the Company facilitates better outcomes for healthcare providers and cardiac rhythm patients with software tools and services essential for their management of these chronically ill patients. The Company provides Software-as-a-Service (SaaS) and Monitoring-as-a-Service (Maas) solutions to meet the needs of health systems, hospitals and private practices throughout the markets in which they operate.

Donald L Deyo is a medtech veteran with extensive experience in development and commercialization of cardiac disease therapies. In the new roles he will guide acceleration of growth in the US and strategic expansion into areas adjacent to and leveraging the Company’s flagship OnePulse™ remote monitoring platform. A former Medtronic executive, Deyo served in various executive roles in Cardiac Rhythm Management (CRM) and Neuromodulation over an extended (29 year) career.

In addition to LindaCare, Deyo currently serves on the board of Nyxoah S.A.  He was a board member for Sapiens Steering Brain Stimulation B.V. prior to acquisition of the company by Medtronic in 2014.  Following Medtronic, Deyo served as President, CEO and board member of FemPulse, Inc and President, CEO and board member of Medallion Therapeutics, both clinical-stage companies developing overactive bladder and targeted drug delivery therapies, respectively.  Deyo also founded the executive consultancy MedTech Execs, which provides strategic and operational services to medical device and pharmaceutical companies.

Commenting on the appointment, Deyo added “I have enjoyed working with the Board and our Founder and CEO, Shahram Sharif, in building our company to this point and am honored to have the opportunity to take on an expanded role in leading the company to its next level of success.”  Sharif added, “Don has been a great partner and mentor for me.  I am looking forward to our expanded partnership and building on our vision for the tremendous potential that is LindaCare.”

SourceLindaCare

Hot this week

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.